Shared Decision-Making in CSU: Choosing Among Oral and Injectable Advanced Therapies

Dr. Chovatiya shifts the conversation to shared decision-making and how to navigate therapy selection when patient preferences are clear—or when they are not. He asks Dr. Tarbox to walk through how she would approach this patient who has stated a preference for oral therapy.

Dr. Tarbox reflects on how profoundly the therapeutic landscape has changed. Before 2014, the only advanced options were one approved injectable biologic or off-label immunosuppressants. Now, dermatologists can offer patients a genuine menu of choices—oral and injectable, fast-acting and longer-sustaining—which makes shared decision-making both more meaningful and more complex. For this patient, his travel schedule makes injection adherence difficult, and the fast onset of action of an oral BTK inhibitor is particularly attractive for someone whose disease is causing acute, unpredictable disability. She notes that while there is strong evidence for a monoclonal anti-IgE antibody specifically for angioedema, the oral BTK inhibitor also has solid data for angioedema relief.

Dr. Friedman adds that he has found the BTK inhibitor easy to use in practice: there are no required pre-treatment labs, no lab monitoring during therapy, and the fast onset means that samples (typically supplied in two-week packs) can be an effective bridge that improves patient motivation to pursue insurance authorization. He counsels patients proactively about the minor mucocutaneous side effect of petechiae or bruising, wanting to get ahead of the conversation before the pharmacist or social media does. He notes that the drug is fast-on but also fast-off: patients who miss doses or lose access can experience disease recurrence within one to two days, which is a real-world limitation not seen with biologics that have prolonged pharmacodynamic effects. He keeps patients on their antihistamines when starting advanced therapy—stopping them prematurely can create a false negative impression of efficacy.

Dr. Hawkes adds that drug-drug interactions and the need to hold the medication before and after surgery should be part of the counseling conversation. Both panelists agree that the ideal endpoint before considering dose de-escalation is complete disease freedom for at least six months.

In the next episode, " A Complex CSU Case: Overlap Urticaria and Treatment History Gaps," the panel introduces Case 3—a patient with established CSU, co-existing dermatographia, and incomplete prior treatment records—and discusses how to confirm the diagnosis and prepare for advanced therapy.